In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Gatifloxacin (GAT) and moxifloxacin (MXF) were evaluated in vitro to determine their activities against Mycobacterium tuberculosis. GAT was subsequently compared in a dose range study to isoniazid (INH) in a murine tuberculosis model. GAT was somewhat less active than INH. GAT and MXF were evaluated in mice infected with M. tuberculosis and were found to have similar activities. GAT was studied alone and in combination with ethambutol, ethionamide (ETA), and pyrazinamide (PZA) and compared to INH and rifampin (RIF). GAT appears to have sufficient activity alone and in combination with ETA with or without PZA to merit evaluation for treatment of tuberculosis.
Alvirez-Freites
Enrique J
EJ
Department of Microbiology and Immunology, Upstate Medical University, State University of New York, Syracuse, New York, USA.
Carter
Janna L
JL
Cynamon
Michael H
MH
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D000995:Antitubercular Agents / Q000494:pharmacology*; D001372:Aza Compounds; D015169:Colony Count, Microbial; D004338:Drug Combinations; D005260:Female; D024841:Fluoroquinolones; D000077734:Gatifloxacin; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D009296:Nasal Cavity / Q000821:virology; D011804:Quinolines; D014376:Tuberculosis / Q000188:drug therapy / Q000382:microbiology
D000890:Anti-Infective Agents; D000995:Antitubercular Agents; D001372:Aza Compounds; D004338:Drug Combinations; D024841:Fluoroquinolones; D011804:Quinolines; D000077734:Gatifloxacin; D000077266:Moxifloxacin; D007538:Isoniazid